<scp>DNL</scp>104, a Centrally Penetrant <scp>RIPK</scp>1 Inhibitor, Inhibits <scp>RIP</scp>1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers
Hendrika W. Grievink(Centre for Human Drug Research), Geert Jan Groeneveld(Leiden University Medical Center)
Cited by 77
Related Papers
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
|Nature Medicine|2024|38
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis
|Science Translational Medicine|2024|31